Skip to main content
SpringerLink
Log in

Laboratory Methods and Management of Patients with Heparin-Induced Thrombocytopenia

  • Protocol
  • First Online:
Anticoagulants, Antiplatelets, and Thrombolytics

Part of the book series: Methods in Molecular Biology ((MIMB,volume 663))

Abstract

The clinical effects of heparin are meritorious and heparin remains the anticoagulant of choice for most clinical needs. However, as with any drug, adverse effects exist. Heparin-induced thrombocytopenia (HIT) is an important adverse effect of heparin associated with amputation and death due to thrombosis. Although the diagnosis and treatment of HIT can be difficult and complex, it is critical that patients with HIT be identified as soon as possible to initiate early treatment to avoid thrombosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kelton, J.G., Sheridan, D., Santos, A., Smith, J., Steeves, K., Smith, C., Brown, C., and Murphy, W.G. (1988) Heparin-induced thrombocytopenia: laboratory studies Blood 72, 925–30.

    PubMed  CAS  Google Scholar 

  2. Amiral, J., Bridey, F., Dreyfus, M., Vissac, M., Fressinaud, E., Wolf, M., and Meyer, D. (1992) Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia Thromb Haemost 68, 95–6.

    PubMed  CAS  Google Scholar 

  3. Greinacher, A., Potzsch, B., Amiral, J., Dummel, V., Eichner, A., and Mueller-Eckhardt, C. (1994) Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen Thromb Haemost 71, 247–51.

    PubMed  CAS  Google Scholar 

  4. Maccarana, M., and Lindahl, U. (1993) Model of interaction between platelet factor 4 and heparin Glycobiology 3, 271–7.

    PubMed  CAS  Google Scholar 

  5. Mayo, K.H., Ilyina, E., Roongta, V., Dundas, M., Joseph, J., Lai, C.K., Maione, T., and Daly, T.J. (1995) Heparin binding to platelet factor-4. An NMR and site-directed .mutagenesis study: arginine residues are crucial for binding Biochem J 312, 357–65.

    PubMed  CAS  Google Scholar 

  6. Newman, P.M., and Chong, B.H. (2000) Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation Blood 96, 182–7.

    PubMed  CAS  Google Scholar 

  7. Suh, J., Aster, R.H., and Visentin, G.P. (1998) Antibodies from patients with heparin-induced thrombocytopenia/throm bosis recognize different epitopes on heparin:platelet factor 4 Blood 91, 916–22.

    PubMed  CAS  Google Scholar 

  8. Visentin, G.P. (1999) Heparin-induced thrombocytopenia: molecular pathogenesis Thromb Haemost 82, 448–56.

    PubMed  CAS  Google Scholar 

  9. Rauova, L., Poncz, M., McKenzie, S.E., Reilly, M.P., Arepally, G., Weisel, J.W., Nagaswami, C., Cines, D.B., and Sachais, B.S. (2005) Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia Blood 105, 131–8.

    PubMed  CAS  Google Scholar 

  10. Visentin, G.P., Ford, S.E., Scott, P.J., and Aster, R.H. (1994) Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells J Clin Invest 93, 81–8.

    PubMed  CAS  Google Scholar 

  11. Newman, P.M., and Chong, W.J. (1999) Further characterization of antibody and antigen in heparin-induced thrombocytopenia Br J Haematol 107, 303–9.

    PubMed  CAS  Google Scholar 

  12. Amiral, J., Marfaing-Koka, M., Wolf, M., Alessi, M.C., Tardy, B., Boyer-Neumann, C., Vissac, A.M., Fressinaud, E., Poncz, M., and Meyer, D. (1996) Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia Blood 88, 410–6.

    PubMed  CAS  Google Scholar 

  13. Regnault, V., deMaistre, E., Carteaux, J., Gruel, Y., and Nguyen, P. (2003) Platelet activation induced by human antibodies to interleukin-8 Blood 101, 1419–21.

    PubMed  CAS  Google Scholar 

  14. Walenga, J.M., Prechel, M.M., Jeske, W.P., and Bakhos, M. (2005) Unfractionated heparin compared with low-molecular-weight heparin as related to heparin-induced thrombocytopenia Curr Opin Pulm Med 11, 385–91.

    PubMed  CAS  Google Scholar 

  15. Jeske, W.P., Walenga, J.M., Szatkowski, E., Ero, M., Herbert, J.M., Haas, S., and Bakhos, M. (1997) Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets Thromb Res 88, 271–81.

    PubMed  CAS  Google Scholar 

  16. Warkentin, T.E., Hayward, C.P., Boshkov, L.K., Santos, A.V., Sheppard, J.A., Bode, A.P., and Kelton. J.G. (1994) Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia Blood 84, 3691–9.

    PubMed  CAS  Google Scholar 

  17. Walenga, J.M., Jeske, W.P., Prechel, M.M., and Bakhos, M. (2004) Newer insights on the mechanism of heparin-induced thrombocytopenia Semin Thromb Hemost 30(Suppl 1), 57–67.

    PubMed  Google Scholar 

  18. Jeske, W.P., Vasaiwala, S., Schlenker, R., Wallis, E., and Walenga, J.M. (2000) Leukocyte activation in heparin-induced thrombocytopenia Blood 96, 29b.

    Google Scholar 

  19. Pouplard, C., Iochmann, S., Renard, B., Herault, P., Colombat, P., Amiral, J., and Gruel, Y. (2001) Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia Blood 97, 3300–2.

    PubMed  CAS  Google Scholar 

  20. Herbert, J.M., Savi, P., Jeske, W.P., and Walenga, J.M. (1998) Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells Thromb Haemost 80, 326–31.

    PubMed  CAS  Google Scholar 

  21. Walenga, J.M., Michal, K., Hoppensteadt, D., Wood, J.J., Bick, R.L., and Robinson, J.A. (1999) Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome Clin Appl Thromb Hemost 5(Suppl 1), S76–S84.

    Google Scholar 

  22. Fareed, J., Walenga, J.M., Hoppensteadt, D.A., Jeske, W.P., Lietz, H.W., Ahmad, S., Callas, D., Messmore, H.L., and Haas, S. (1999) Selectins in the HIT syndrome: pathophysiologic role and therapeutic modulation Semin Thromb Hemost 25(Suppl 1), 37–42.

    PubMed  CAS  Google Scholar 

  23. Blank, M., Shoenfeld, Y., Tavor, S., Praprotnik, S., Boffa, M.C., Weksler, B., Walenga, J.M., Amiral, J., and Eldor, A. (2002) Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells Int Immunol 14, 121–9.

    PubMed  CAS  Google Scholar 

  24. Matsuo, T., Tomaru, T., Kario, K., and Hirokawa, T. (2005) Incidence of heparin-PF4 complex antibody formation and heparin-induced thrombocytopenia in acute coronary syndrome Thromb Res 115, 475–81.

    PubMed  CAS  Google Scholar 

  25. Opatrny, L., and Warner, M.N. (2004) Risk of thrombosis in patients with malignancy and heparin-induced thrombocytopenia Am J Hematol 76, 240–4.

    PubMed  Google Scholar 

  26. Reininger, C.B., Greinacher, A., Graf, J., Lassila, R., Steckmeier, B., and Schwieberer, L. (1996) Platelets of patients with peripheral arterial disease are hypersensitive to heparin Thromb Res 81, 641–9.

    PubMed  CAS  Google Scholar 

  27. Warkentin, T.E., Sheppard, J.A., Horsewood, P., Simpson, P.J., and Moore, J.C. (2000) Impact of the patient population on the risk for heparin-induced thrombocytopenia Blood 96, 1703–8.

    PubMed  CAS  Google Scholar 

  28. Shuster, T.A., Silliman, W.R., Coats, R.D., Mureebe, L., and Silver, D. (2003) Heparin-induced thrombocytopenia: twenty-nine years later J Vasc Surg 38, 1316–22.

    PubMed  Google Scholar 

  29. Warkentin, T.E., and Greinacher, A. (2004) Heparin-induced thrombocytopenia: recognition, treatment, and prevention Chest 126, 311S–37S.

    PubMed  CAS  Google Scholar 

  30. Warkentin, T.E., and Crowther, M.A. (2007) When is HIT really HIT? Ann Thorac Surg 83, 21–3.

    PubMed  Google Scholar 

  31. Lo, G.K., Juhl, D., Warkentin, T.E., Sigouin, C.S., Eichler, P., and Greinacher, A. (2006) Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings J Thromb Haemost 4, 759–65.

    PubMed  CAS  Google Scholar 

  32. Pouplard, C., Amiral, J., Borg, J.Y., Laporte-Simitsidis, S., Delahousse, B., and Gruel, Y. (1999) Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia Am J Clin Pathol 111, 700–6.

    PubMed  CAS  Google Scholar 

  33. Arepally, G.M., and Ortel, T.L. (2006) Clinical practice. Heparin-induced thrombocytopenia N Engl J Med 355, 809–17.

    PubMed  CAS  Google Scholar 

  34. Parker, R.I. (2007) Measurement of heparin-dependent platelet antibodies in the diagnosis of heparin-induced thrombocytopenia: fact or fiction? Crit Care Med 35, 1784–5.

    PubMed  Google Scholar 

  35. Lillo-Le Louet, A., Boutouyrie, P., Alhenc-Gelas, M., Le Beller, C., Gautier, I., Aiach, M., and Lasne, D. (2004) Diagnostic score for heparin induced thrombocytopenia after cardiopulmonary bypass J Thromb Haemost 2, 1882–8.

    Google Scholar 

  36. Chan, M., Malynn, E., Shaz, B., and Uhl, L. (2008) Utility of consecutive repeat HIT ELISA testing for heparin-induced thrombocytopenia Am J Hematol 83, 212–7.

    PubMed  Google Scholar 

  37. Izban, K.F., Lietz, J.W., Hoppensteadt, D.A., Jeske, W.P., Fareed, J., Bakhos, M., and Walenga, J.M. (1999) Comparison of two PF4/Heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia Semin Thromb Hemost (Suppl 1) 25, 51–6.

    CAS  Google Scholar 

  38. Warkentin, T.E., and Greinacher, A. (2007) Laboratory testing for heparin-induced thrombocytopenia In: Warkentin, T.E., and Greinacher, A., eds. Heparin-Induced Thrombocytopenia, 4th edition. New York: Informa Healthcare; 2007:227–60.

    Google Scholar 

  39. Martin-Toutain, I., Piette, J.C., Diemert, M.C., Faucher, C., Jobic, L., and Ankri, A. (2007) High prevalence of antibodies to platelet factor 4 heparin in patients with antiphospholipid antibodies in absence of heparin-induced thrombocytopenia Lupus 16, 79–83.

    PubMed  CAS  Google Scholar 

  40. Warkentin, T.E., Sheppard, J.A., Moore, J.C., Moore, K.M., Sigouin, C.S., and Kelton, J.G. (2005) Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class to we need? J Lab Clin Med 146, 341–6.

    PubMed  CAS  Google Scholar 

  41. Juhl, D., Eichler, P., Lubenow, N., Strobel, U., Wessel, A., and Greinacher, A. (2006) Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patients samples referred for diagnostic testing for heparin-induced thrombocytopenia Eur J Haematol 76, 420–6.

    PubMed  Google Scholar 

  42. ISTH Platelet Immunology, Scientific Subcommittee. Chairs: Warkentin T, Chong B, Greinacher A, Gruel Y, Kiefel V, Kroll H. July 6, 2007, Palexpo, Geneva, Switzerland. Available at http://www.isth2007.com, Accessed on Dec. 6, 2007.

  43. Alberio, L., Kimmerle, S., Baumann, A., Taleghani, B.M., Biasiutti, F.D., and Lammle, B. (2003) Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia Am J Med 114, 528–36.

    PubMed  CAS  Google Scholar 

  44. Francis, J.L. (2003) A critical evaluation of assays for detecting antibodies to the heparin-PF4 complex Semin Thromb Hemost 30, 359–68.

    Google Scholar 

  45. Francis, J.L., Drexler, A., Duncan, M.K., Desai, H., Amaya, M., Robson, T., Meyer, T.V., Reyes, E., Rathmann, K., and Amirkhosravi, A. (2006) Prospective evaluation of laboratory tests for the diagnosis of heparin-induced thrombocytopenia Blood 108, 312a–3a.

    Google Scholar 

  46. Low, J., Austin, S., Bryant, A., and Joseph, J. (2007) Combining 4T’s pre-test clinical score and ID-PAGIA heparin/PF4 test to exclude heparin induced thrombocytopenia (HIT) J Thromb Haemost (Suppl 2) 5, P-W-332.

    Google Scholar 

  47. Walenga, J.M., Jeske, W.P., Fasanella, A.R., Wood, J.J., and Bakhos, M. (1999) Laboratory tests for the diagnosis of heparin-induced thrombocytopenia Semin Thromb Hemost (Suppl 1) 25, 43–9.

    CAS  Google Scholar 

  48. Chong, B.H., Burgess, J., and Ismail, F. (1993) The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia Thromb Haemost 69, 344–50.

    PubMed  CAS  Google Scholar 

  49. Warkentin, T.E., Hayward, C.P.M., Smith, C.A., Kelly, P.M., and Kelton, J.G. (1992) Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia J Lab Clin Med 120, 371–9.

    PubMed  CAS  Google Scholar 

  50. Eichler, P., Budde, U., Haas, S., Kroll, H., Loreth, R.M., Meyer, O., Pachmann, U., Potzsch, B., Schabel, A., Albrecht, D., and Greinacher, A. (1999) First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA Thromb Haemost 81, 625–9.

    PubMed  CAS  Google Scholar 

  51. Greinacher, A., Michels, I., Kiefel, V., and Mueller-Eckhardt, C. (1991) A rapid and sensitive test for diagnosing heparin-induced thrombocytopenia Thromb Haemost 66, 734–6.

    PubMed  CAS  Google Scholar 

  52. Tomer, A. (1997) A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia Br J Haematol 98, 648–56.

    PubMed  CAS  Google Scholar 

  53. Tomer, A., Masalunga, C., and Abshire, T.C. (1999) Determination of heparin-induced thrombocytopenia: a rapid flow cytometric assay for direct demonstration of antibody-mediated platelet activation Am J Hematol 61, 53–61.

    PubMed  CAS  Google Scholar 

  54. Stewart, M.W., Etches, W.S., Boshkov, L.K., and Gordon, P.A. (1995) Heparin-induced thrombocytopenia: an improved method of detection based on lumi-aggregomaetry Br J Haematol 91, 173–7.

    PubMed  CAS  Google Scholar 

  55. Pouplard, C., Gueret, P., Fouassier, M., Ternisien, C., Trossaert, M., and Regina, S. (2007) Prospective evaluation of the ‘4Ts’ score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia J Thromb Haemost 5, 1373–9.

    PubMed  CAS  Google Scholar 

  56. Warkentin, T.E. (2002) Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia Arch Path Lab Med 126, 1415–23.

    PubMed  Google Scholar 

  57. Zwicker, J.I., Uhl, L., Huang, W.-Y., Shaz, B.H., and Bauer, K.A. (2004) Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia J Thromb Haemost 2, 2133–7.

    PubMed  CAS  Google Scholar 

  58. Altunas, F., Matevosyan, K., Burner, J., Shen, Y.M., and Sarode, R. (2008) Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia Eur J Haematol 80, 429–35.

    Google Scholar 

  59. Refaai, M.A., Laposata, M., and VanCott, E.M. (2003) Clinical significance of a borderline titer in a negative ELISA test for heparin-induced thrombocytopenia Am J Clin Pathol 119, 61–5.

    PubMed  Google Scholar 

  60. Smythe, M.A., Koerber, J.M., and Mattson, J.C. (2005) An evaluation of heparin platelet factor 4 antibody testing J Thromb Haemost (Suppl 1) 3, P1516.

    Google Scholar 

  61. Stribling, W.K., Slaughter, T.F., Houle, T.T., and Sane, D.C. (2007) Beyond the platelet count: heparin antibodies as independent risk predictors Am Heart J 153, 900–6.

    PubMed  CAS  Google Scholar 

  62. Mattioli, A.V., Bonetti, L., Sternieri, S., and Mattioli, G. (2000) Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up Ital Heart J 1, 39–42.

    PubMed  CAS  Google Scholar 

  63. Williams, R.T., Damaraju, L.V., Mascelli, M.A., Barnathan, E.S., Califf, R.M., Simoons, M.L., Deliargyris, E.N., and Sane, D.C. (2003) Anti-platelet factor 4/heparin antibodies: an independent predictor of 30 day myocardial infarction after acute coronary syndromes Circulation 107, 2307–12.

    PubMed  Google Scholar 

  64. Bennett-Guerrero, E., Slaughter, T.F., White, W.D., Welsby, I.J., Greenberg, C.S., El-Moalem, H., and Ortel, T.L. (2005) Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery J Thorac Cardiovasc Surg 130, 1567–72.

    PubMed  CAS  Google Scholar 

  65. Pena de la Vega, L., Miller, R.S., Benda, M.M., Grill, D.E., Johnson, M.G., McCarthy, J.T., and McBane, R. (2005) Association of heparin-dependent antibodies and adverse outcomes in hemodialysis patients: a population-based study Mayo Clin Proc 80, 995–1000.

    Google Scholar 

  66. Lindhoff-Last, E., Eicher, P., Stein, M., Plagemann, J., Gerdsen, F., Wagner, R., Ehrly, A.M., and Bauersachs, R. (2000) A prospective study on the incidence and clinical relevance of heparin-induced antibodies in patients after vascular surgery Thromb Res 97, 387–93.

    PubMed  CAS  Google Scholar 

  67. Warkentin, T.E., Levine, M.N., Hirsch, J., Horsewood, P., Roberts, R.S., Gent, M., and Kelton, J.G. (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin N Engl J Med 332, 1330–5.

    PubMed  CAS  Google Scholar 

  68. Carrier, M., Rodger, M.A., Fergusson, D., Doucette, S., Kovacs, M.J., Moore, J., Kelton, J.G., and Knoll, G.A. (2008) Increased mortality in hemodialysis patients having specific antibodies to the platelet factor 4-heparin complex Kidney Internat 73, 213–9.

    CAS  Google Scholar 

  69. Wallis, D.E., Workman, D.L., Lewis, B.F., Pifarré, R., and Moran, J.F. (1999) Failure of early heparin cessation as a treatment for heparin-induced thrombocytopenia Am J Med 106, 629–35.

    PubMed  CAS  Google Scholar 

  70. Messmore, H.L., Jeske, W.P., Wehrmacher, W.H., and Walenga, J.M. (2003) Benefit-risk assessment of treatments for heparin-induced thrombocytopenia Drug Safety 26, 625–41.

    PubMed  CAS  Google Scholar 

  71. Lewis, B.E., Wallis, D.E., Berkowitz, S.D., Matthai, W.H., Fareed, J., Walenga, J.M., Bartholomew, J., Sham, R., Lerner, R.G., Zeigler, Z.R., Rustagi, P.K., Jang, I.K., Rifkin, S.D., Moran, J., Hursting, M.J., Kelton, J.G., and for the ARG-911 Study Investigators (2001) Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia Circulation 103, 1838–43.

    PubMed  CAS  Google Scholar 

  72. Lewis, B.E., Wallis, D.E., Leya, F., Hursting, M.J., Kelton, J.G., and for the Argatroban-915 Investigators (2003) Argatroban anticoagulation in patients with heparin-induced thrombocytopenia Arch Intern Med 163, 1849–56.

    PubMed  CAS  Google Scholar 

  73. Greinacher, A., Völpel, H., Janssens, U., Hach-Wunderle, V., Kemkes-Matthes, B., Eichler, P., Mueller-Velten, H.G., Potzsch, B., and for the HIT Investigators Group (1999) Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study Circulation 99, 73–80.

    PubMed  CAS  Google Scholar 

  74. Greinacher, A., Janssens, U., Berg, G., Bock, M., Kwasny, H., Kemkes-Matthes, B., Eichler, P., Volpel, H., Potzsch, B., Luz, M., and for the HAT Investigators (1999) Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia Circulation 100, 587–93.

    PubMed  CAS  Google Scholar 

  75. Walenga, J.M., Fasanella, A.R., Iqbal, O., Hoppensteadt, D.A., Ahmad, S., Wallis, D.E., and Bakhos, M. (1999) Coagulation laboratory testing in patients treated with argatroban Semin Thromb Hemost 25(Suppl 1), 61–6.

    PubMed  CAS  Google Scholar 

  76. Walenga, J.M., Drenth, A.F., Mayuga, M., Hoppensteadt, D.A., Prechel, M.M., Harder, S., Watanabe, H., Osakabe, M., and Breddin, H.K. (2008) Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effect on coagulation factor testing Clin Appl Thromb Hemost 14, 325–31.

    PubMed  CAS  Google Scholar 

  77. Hirsh, J., Heddle, N., and Kelton, J.G. (2004) Treatment of heparin-induced thrombocytopenia Arch Intern Med 164, 361–9.

    PubMed  CAS  Google Scholar 

  78. Warkentin, T.E. (2003) Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban Thromb Res 110, 73–82.

    PubMed  CAS  Google Scholar 

  79. LeMonte, M.P., Brown, P.M., and Hursting, M.J. (2005) Alternative parenteral anticoagulation with argatroban, a direct thrombin inhibitor Expert Rev Cardiovasc Ther 3, 31–41.

    Google Scholar 

  80. Lewis, B.E., Walenga, J.M., and Hursting, M.J. (2002) Argatroban anticoagulation in patients with heparin-induced thrombocytopenia Cardiovasc Rev Rep 23, 445–57.

    CAS  Google Scholar 

  81. Swan, S.K., and Hursting MJ. (2000) The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction Pharmacotherapy 20, 318–29.

    PubMed  CAS  Google Scholar 

  82. Swan, S.K., St. Peter, J.V., Lambrecht, L.J., and Hursting, M.J. (2000) Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects Pharmacotherapy 20, 756–70.

    PubMed  CAS  Google Scholar 

  83. Matthai, W.H., Jr., Hursting, M.J., Lewis, B.E., and Kelton, J.G. (2005) Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia Thromb Res 116, 121–6.

    PubMed  CAS  Google Scholar 

  84. Walenga, J.M., Ahmad, S., Hoppensteadt, D., Iqbal, O., Hursting, M.J., and Lewis, B.E. (2002) Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia Thromb Res 105, 401–5.

    PubMed  CAS  Google Scholar 

  85. Walenga, J.M., Fareed, D., Schultz, C., Neville, B., and Hoppensteadt, D. (2004) Argatroban, not lepirudin or bivalirudin, treatment results in the generation of nitric oxide during parenteral administration Blood 104, 512a.

    Google Scholar 

  86. Lewis, B.E., Matthai, W.H., Cohen, M., Moses, J., Hursting, J., and Leya F. (2002) Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia Cathet Cardiovasc Intervent 57, 177–84.

    Google Scholar 

  87. Cornell, T., Wyrick, P., Fleming, G., Pasko, D., Han, Y., Custer, J., Haft, J., and Annich, G. (2007) A case series describing the use of argatroban in patients on extracorporeal circulation ASAIO J 53, 460–3.

    PubMed  CAS  Google Scholar 

  88. Potter, K.E., Raj, A., and Sullivan, J.E. (2007) Argatroban for anticoagulation in pediatric patients with heparin-induced thrombocytopenia requiring extracorporeal life support J Ped Hematol Oncol 29, 265–8.

    CAS  Google Scholar 

  89. Jang, I., and Hurstings, M.J. (2005) When heparins promote thrombosis: review of heparin-induced thrombocytopenia Circulation 111, 2671–83.

    PubMed  Google Scholar 

  90. Cetta, F., Graham, L.C., Wrona, L.L., Arruda, M.J., and Walenga, J.M. (2004) Argatroban use during pediatric interventional cardiac catheterization Cathet Cardiovasc Intervent 61, 147–9.

    Google Scholar 

  91. Jang, I.K., Lewis, B.E., Matthai, W.H., and Kleiman, N.S. (2004) Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, nonrandomized pilot study J Thromb Thrombol 18, 31–7.

    CAS  Google Scholar 

  92. LaMonte, M.P., Brown, P.M., and Hursting, M.J. (2004) Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy Crit Care Med 32, 976–80.

    PubMed  CAS  Google Scholar 

  93. Eichler, P., Friesen, H.J., Lubenow, N., Jaeger, B., and Greinacher, A. (2000) Anti-hirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance Blood 96, 2373–8.

    PubMed  CAS  Google Scholar 

  94. Greinacher, A., Eichler, P., Albrecht, D., Strobel, U., Potzsch, B., and Eriksson, B.I. (2003) Anti-hirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance Blood 101, 2617–9.

    PubMed  CAS  Google Scholar 

  95. Fischer, K.G., Liebe, V., Hudek, R., Piazolo, L., Haase, K.K., Borggrefe, M., and Huhle, G. (2003) Anti-hirudin antibodies alter pharmacokinetics and pharmacodynamics of recombinant hirudin Thromb Haemost 89, 973–82.

    PubMed  CAS  Google Scholar 

  96. Greinacher, A., Lubenow, N., and Eichler, P. (2003) Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia (HIT) Circulation 108, 2062–5.

    PubMed  CAS  Google Scholar 

  97. Cochran, K., DeMartini, T.J., Lewis, B.E., O’Brien, J., Steen, L.H., Grassman, E.D., and Leya, F. (2003) Use of lepirudin during percutaneous vascular interventions in patients with heparin-induced thrombocytopenia J Invas Cardiol 15, 622–3.

    Google Scholar 

  98. Mahaffey, K.W., Lewis, B.E., Wildermann, N.M., Berkowitz, S.D., Oliverio, R.M., Turco, M.A., Shalev, Y., Lee, P.V., Traverse, J.H., Rodriguez, A.R., Ohman, E.M., Harrington, R.A., Califf, R., and for the ATBAT Investigators (2003) The anticoagulant therapy with bivalirudin to assist in the performance of PCI in patients with heparin-induced thrombocytopenia (ATBAT) study J Invas Cardiol 15, 611–6.

    Google Scholar 

  99. Merry, A.F., Raudkivi, P.J., Middleton, N.G., McDougall, J.M., Nand, P., Mills, B.P., Webber, B.J., Frampton, C.M., and White, H.D. (2004) Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery Ann Thorac Surg 77, 925–31.

    PubMed  Google Scholar 

  100. Koster, A., Spiess, B., Chew, D.P., Krabatsch, T., Tambeur, L., DeAnda, A., Hetzer, R., Kuppe, H., Smedira, N.G., and Lincoff, A.M. (2004) Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting Am J Cardiol 93, 356–9.

    PubMed  CAS  Google Scholar 

  101. Magnani, H.N., and Gallus, A. (2006) Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004 Thromb Haemost 95, 967–81.

    PubMed  CAS  Google Scholar 

  102. Lindhoff-Last, E., Kreutzenbeck, H-J., and Magnani H.N. (2005) Treatment of 51 pregnancies with danaparoid because of heparin intolerance Thromb Haemost 93, 63–9.

    PubMed  CAS  Google Scholar 

  103. Chong, B.H., Gallus, A.S., Cade, J.F., Magnani, H., Manoharan, A., Oldmeadow, M., and for the Australian HIT Study Group (2001) Prospective randomized open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis Thromb Haemost 86, 1170–5.

    PubMed  CAS  Google Scholar 

  104. Farner, B., Eichler, P., Kroll, H., and Greinacher, A. (2001) A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia Thromb Haemost 85, 950–7.

    PubMed  CAS  Google Scholar 

  105. Walenga, J.M., Koza, M.J., Lewis, B.E., and Pifarré, R. (1996) Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents Clin Appl Thromb Hemost 2(Suppl 1), S21–7.

    Google Scholar 

  106. Elalamy, I., Lecrubier, C., Horellou, M.H., Conard, J., and Samama, M.M. (2000) Heparin-induced thrombocytopenia: laboratory management Ann Med 32(Suppl 1), 60–7.

    PubMed  CAS  Google Scholar 

  107. Parody, R., Oliver, A., Souto, J.C., and Fontcuberta, J. (2003) Fondaparinux (Arixtra) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins Haematologica 88, ECR32.

    PubMed  Google Scholar 

  108. D’Amico, E.A., Villaca, P.R., Gualandro, S.F., Bassitt, R.P., and Chamone, D.A. (2003) Successful use of Arixtra in a patient with paroxysmal nocturnal hemoglobinuria, Budd-Chiari syndrome and heparin-induced thrombocytopenia J Thromb Haemost 1, 2452–3.

    PubMed  Google Scholar 

  109. Bradner, J., Hallisey, R.K., and Kuter, D.J. (2004) Fondaparinux in the treatment of heparin-induced thrombocytopenia Blood 104, Abstract 1775.

    Google Scholar 

  110. Lobo, B., Finch, C., Howard, A., and Minhas S. (2008) Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia Thromb Haemost 99, 208–14.

    PubMed  CAS  Google Scholar 

  111. Warkentin TE, Maurer, B.T., and Aster, R.H. (2007) Heparin-induced thrombocytopenia associated with fondaparinux N Engl J Med 356, 2653–5.

    PubMed  CAS  Google Scholar 

  112. Rota, E., Bazzan, M., and Fantino, G. (2008) Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT) Thromb Haemost 99, 779–81.

    PubMed  CAS  Google Scholar 

  113. Warkentin, T.E., Cook, R.J., Marder, V.J., Sheppard, J.A., Moore, J.C., Eriksson, B.I., Greinacher, A., and Kelton, J.G. (2005) Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin Blood 106, 3791–6.

    Google Scholar 

  114. Eriksson, B.I., Borris, L.C., Dahl, O.E., Haas, S., Huisman, M.V., Kakkar, A.K., Misselwitz, F., Muehlhofer, E., and Kalebo, P. (2007) Dose-escalation study of rivaroxaban (BAY 59-7939), an oral, direct factor Xa inhibitor, for the prevention of venous thromboembolism in patients undergoing total hip replacement Thromb Res 120, 685–93.

    PubMed  CAS  Google Scholar 

  115. Agnelli, G., Gallus, A., Goldhaber, S.Z., Haas, S., Huisman, M.V., Hull, R.D., Kakkar, A.K., Misselwitz, F., Schellong, S., and for the ODIXa-DVT Study Investigators. (2007) Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study Circulation 116, 180–7.

    PubMed  CAS  Google Scholar 

  116. Erikkson, B.I., Borris, L.C., Dahl, O.E., Haas, S., Huisman, M.V., Kakkar, A.K., Muehlhofer, E., Dierig, C., Misselwitz, F., Kalebo, P., and for the ODIXa-HIP Study Investigators. (2006) A once-daily, oral direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement Circulation 114, 2374–81.

    Google Scholar 

  117. Lassen, M.R., Davidson, B.L., Gallus, A., Pineo, G., Ansell, J., and Deitchman, D. (2007) The efficacy and safety of apixban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement J Thromb Haemost 5, 2368–75.

    PubMed  CAS  Google Scholar 

  118. Walenga, J.M., Jeske, W.P., Prechel, M., Hoppensteadt, D., Swank, J., Sheen, L., Misselwitz, F., Messmore, H., and Bakhos, M. (2007) Potential of the factor Xa inhibitor rivaroxaban for the anticoagulation management of patients with heparin-induced thrombocytopenia J Thromb Haemost 5(Suppl 2), P-M-648.

    Google Scholar 

  119. Wallis, D.E., Quintos, R., Wehrmacher, W., and Messmore, H.L. (1999) Safety of warfarin anticoagulation in patients with heparin-induced thrombocytopenia Chest 116, 1333–8.

    PubMed  CAS  Google Scholar 

  120. Gosselin, R.C., Dager, W.E., King, J.H., Janatpour, K., Mahackian, K., Larkin, E.C., and Owings, J.T. (2004) Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values Am J Clin Pathol 121, 593–9.

    PubMed  CAS  Google Scholar 

  121. Sheth, S.B., DiCicco, R.A., Hursting, M.J., Montague, T., and Jorkasky, D.K. (2001) Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin Thromb Haemost 85, 435–40.

    PubMed  CAS  Google Scholar 

  122. Harder, S., Graff, J., Klinkhardt, U., von Hentig, N., Walenga, J.M., Watanabe, H., Osakabe, M., and Breddin, H.K. (2004) Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on PT, aPTT, and ecarin clotting time Thromb Haemost 91, 1137–45.

    PubMed  CAS  Google Scholar 

  123. Hursting, M.J., Lewis, B.E., and Macfarlane, D.E. (2005) Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia Clin Appl Thromb Hemost 11, 279–87.

    PubMed  CAS  Google Scholar 

  124. Pötzsch, B., and Klovekorn, W.P. (2000) Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia N Engl J Med 343, 515–6.

    PubMed  Google Scholar 

  125. Walenga, J.M., Jeske, W.P., Wallis, D.E., Bakhos, M., Lewis, B.E., Leya, F., and Fareed, J. (1999) Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT Semin Thromb Hemost 25(Suppl 1), 77–81.

    PubMed  CAS  Google Scholar 

  126. Walenga, J.M., Lewis, B.E., Jeske, W.P., Leya, F., Wallis, D.E., Bakhos, M., and Fareed, J. (1999) Combined thrombin and platelet inhibition treatment for HIT patients Hämostaseologie 19, 128–33.

    CAS  Google Scholar 

  127. Haas, S., Walenga, J.M., Jeske, W.P., and Fareed, J. (1999) Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications Semin Thromb Hemost 25(Suppl 1), 67–75.

    PubMed  CAS  Google Scholar 

  128. Fareed, J., Bick, R.L., Rao, G., Goldhaber, S.Z., Sasahara, A., Messmore, H.L., Hoppensteadt, D.A., and Nicolaides, A. (2008) The immunogenic potential of generic versions of low-molecular weight heparins may not be the same as the branded products Clin Appl Thromb Hemost 14, 5–7.

    PubMed  Google Scholar 

  129. Houiste, C., Auguste, C., Macrez, C., Dereux, S., Derouet, A., and Anger, P. (2009) Quantitative PCR and disaccharide profiling to characterize the animal origin of low-molecular-weight heparins Clin Appl Thromb Hemost 15, 50–8.

    PubMed  CAS  Google Scholar 

  130. Kishimoto, T.K., Viswanathan, K., Ganguly, T., Elankumaran, S., Smith, S., Pelzer, K., Lansing, J.C., Sriranganathan, N., Zhao, G., Galcheva-Gargova, Z., Al-Hakim, A., Bailey, G.S., Fraser, B., Roy, S., Rogers-Cotrone, T., Buhse, L., Whary, M., Fox, J., Nasr, M., Dal Pan, G.J., Shriver, Z., Langer, R.S., Venkataraman, G., Austen, K.F., Woodcock, J., and Sasisekharan, R. (2008) Contaminated heparin associated with adverse clinical events and activation of the contact system N Engl J Med 358, 2457–67.

    PubMed  CAS  Google Scholar 

  131. Guerrini, M., Beccati, D., Shriver, Z., Naggi, A., Viswanathan, K., Bisio, A., Capila, I., Lansing, J.C., Guglieri, S., Fraser, B., Al-Hakim, A., Gunay, N.S., Zhang, Z., Robinson, L., Buhse, L., Nasr, M., Woodcock, J., Langer, R., Venkataraman, G., Linhardt, R.J., Casu, B., Torri, G., and Sasisekharan, R. (2008) Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events Nat Biotechnol 26, 669–75.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Stritch School of Medicine, Loyola University, Maywood, IL, USA

    Margaret Prechel

  2. Department of Thoracic & Cardiovascular Surgery, Stritch School of Medicine, Loyola University, Maywood, IL, USA

    Walter P. Jeske & Jeanine M. Walenga

Authors
  1. Margaret Prechel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Walter P. Jeske
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeanine M. Walenga
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. , Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sc, Discovery Drive One, Rensselaer, 12144, New York, USA

    Shaker A. Mousa

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Prechel, M., Jeske, W.P., Walenga, J.M. (2010). Laboratory Methods and Management of Patients with Heparin-Induced Thrombocytopenia. In: Mousa, S. (eds) Anticoagulants, Antiplatelets, and Thrombolytics. Methods in Molecular Biology, vol 663. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-803-4_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-803-4_4

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-802-7

  • Online ISBN: 978-1-60761-803-4

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation